Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.
Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.
David Tepper's Appaloosa LP renews calls for changes at the top.
Let's see what the charts and indicators look like.
Analysts have noted that the weed leader's momentum is set to burn higher moving forward.
In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Pfizer may have poked the bear.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
Once the safest stocks in the book, the big-cap drug companies are now toxic.